Evidence map›Paper›PMID 39560477›Full record

ReviewRadiology2024

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.

Ryan Bitar, Riad Salem, Richard Finn, Tim F Greten, S Nahum Goldberg, Julius Chapiro

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Cytotoxic Activity ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Impact of LEAP-012 and EMERALD-1 in the management of HCC.JHEP reports : innovation in hepatology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ryan BitarFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).ORCID 0000-0002-1311-2234
Riad SalemFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).
Richard FinnFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).ORCID 0000-0003-2494-2126
Tim F GretenFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).ORCID 0000-0002-0806-2535
S Nahum GoldbergFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).ORCID 0000-0003-2940-9822
Julius ChapiroFrom the Departments of Radiology (R.B., J.C.) and Digestive Diseases (Hepatology) (J.C.), Yale University School of Medicine, New Haven, Conn; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (R.S.); Department of Medical Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (R.F.); Center for Cancer Research, National Institutes of Health, Bethesda, Md (T.F.G.); Department of Radiology, Hadassah Hebrew University Medical Center, Hebrew University, Jerusalem, Israel (S.N.G.); and Department of Biomedical Engineering, Yale School of Engineering and Applied Sciences, 789 Howard Ave, Clinic Bldg 363H, New Haven, CT 06520 (J.C.).ORCID 0000-0002-1984-2246

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of hepatocellular carcinoma (HCC) is undergoing transformational changes due to the emergence of various novel immunotherapies and their combination with image-guided locoregional therapies. In this setting, immunotherapy is expected to become one of the standards of care in both neoadjuvant and adjuvant settings across all disease stages of HCC. Currently, more than 50 ongoing prospective clinical trials are investigating various end points for the combination of immunotherapy with both percutaneous and catheter-directed therapies. This review will outline essential tumor microenvironment mechanisms responsible for disease evolution and therapy resistance, discuss the rationale for combining locoregional therapy with immunotherapy, summarize ongoing clinical trials, and report on developing imaging end points and novel biomarkers that are relevant to both diagnostic and interventional radiologists participating in the management of HCC.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsCombined Modality TherapyHumansRadiology, InterventionalTumor Microenvironment

Identifiers

PMID39560477
PMCPMC11605110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.